IRIS

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial / Eggermont, Amm; Blank, Cu; Mandala, M; Long, Gv; Atkinson, Vg; Dalle, S; Haydon, Am; Meshcheryakov, A; Khattak, A; Carlino, Ms; Sandhu, S; Larkin, J; Puig, S; Ascierto, P; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Di Giacomo, Am; Van Den Eertwegh, Ajm; Grob, Jj; Gutzmer, R; Jamal, R; Lorigan, Pc; Van Akkooi, Acj; Krepler, C; Ibrahim, N; Marreaud, S; Kicinski, M; Suciu, S; Robert, C. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 38:33(2020). [10.1200/JCO.20.02110]

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Ascierto P;
2020
2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial / Eggermont, Amm; Blank, Cu; Mandala, M; Long, Gv; Atkinson, Vg; Dalle, S; Haydon, Am; Meshcheryakov, A; Khattak, A; Carlino, Ms; Sandhu, S; Larkin, J; Puig, S; Ascierto, P; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Di Giacomo, Am; Van Den Eertwegh, Ajm; Grob, Jj; Gutzmer, R; Jamal, R; Lorigan, Pc; Van Akkooi, Acj; Krepler, C; Ibrahim, N; Marreaud, S; Kicinski, M; Suciu, S; Robert, C. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 38:33(2020). [10.1200/JCO.20.02110]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014337
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 259
  • ???jsp.display-item.citation.isi??? 240
social impact